Diabetes, metformin use, and colon cancer: a population-based cohort study in Taiwan.

  title={Diabetes, metformin use, and colon cancer: a population-based cohort study in Taiwan.},
  author={Chin-Hsiao Tseng},
  journal={European journal of endocrinology},
  volume={167 3},
  • C. Tseng
  • Published 1 September 2012
  • Medicine
  • European journal of endocrinology
OBJECTIVE A retrospective cohort study, using a population-based reimbursement database, was conducted for investigating the relationship between diabetes and colon cancer and assessing whether metformin had a protective effect. METHODS Overall, 493,704 men and 502,139 women, covered by the National Health Insurance, without colon cancer were followed from 2003 to 2005. Cox regression evaluated the adjusted relative risk (RR), considering confounders and detection examinations. RESULTS Even… 

Figures and Tables from this paper

Metformin, Statin Use, and Female Colorectal Cancer: A Population-Based Cohort Study in Taiwan

It is indicated that metformin and statin use showed no protective effect against female colorectal cancer (CRC), and an additional randomized trial is necessary to investigate the effect of met formin andstatin use in CRC prevention.

A Cohort Study of Metformin and Colorectal Cancer Risk among Patients with Diabetes Mellitus

The findings showed an inverse association between long-term use of metformin and colorectal cancer risk, which suggests met formin may have a role in the chemoprevention of coloreCTal cancer.

Metformin Reduces Thyroid Cancer Risk in Taiwanese Patients with Type 2 Diabetes

Evidence is provided for the first time that metformin use in patients with type 2 diabetes may reduce the risk of thyroid cancer.

Thyroid Cancer Risk Is Not Increased in Diabetic Patients

There is a lack of an overall association between diabetes and thyroid cancer, but patients with diabetes duration <5 years have a significantly lower risk, and male sex, hypertension, dyslipidemia, chronic obstructive pulmonary disease, vascular complications or use of statin, aspirin or non-steroidal anti-inflammatory drugs might be associated with a significantly higher risk.

Metformin reduces gastric cancer risk in patients with type 2 diabetes mellitus

In conclusion, metformin significantly reduces gastric cancer risk, especially when the cumulative duration is more than approximately 2 years.

Metformin and lung cancer risk in patients with type 2 diabetes mellitus

It is shown that metformin use may reduce lung cancer risk in patients with newly diagnosed type 2 diabetes mellitus and sensitivity analyses after excluding patients with certain risk factors of cancer and subgroup analyses supported a favorable effect of met formin.

Positive effect of metformin treatment in colorectal cancer patients with type 2 diabetes: national cohort study

Investigating colorectal cancer risk in patients with type 2 diabetes mellitus using metformin found decreased with increasing cumulative dose of meetformin indicates that met formin may be a protective agent for coloreCTal cancer development.

Metformin may reduce bladder cancer risk in Taiwanese patients with type 2 diabetes

It is suggested that metformin use is associated with a decreased risk of bladder cancer in patients with T2DM.

Metformin use and cervical cancer risk in female patients with type 2 diabetes

In conclusion, metformin may significantly reduce the risk of cervical cancer, especially when the cumulative duration is more than 2 years.



Metformin Associated With Lower Cancer Mortality in Type 2 Diabetes

In this study, 1,353 patients with type 2 diabetes enrolled in the Zwolle Outpatient Diabetes project Integrating Available Care study in the Netherlands were enrolled in a prospectively followed cohort, and metformin use was associated with lower cancer mortality compared with nonuse of met formin.

Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan

The association with urinary tract diseases suggests a complex scenario in the link between bladder cancer and diabetes at different disease stages, and patients with diabetes have a higher risk of bladder cancer.

Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis

A comprehensive literature search and meta-analysis of epidemiologic studies to assess the effect of metformin on cancer incidence and mortality in diabetic patients found that the inverse association was significant for pancreatic and hepatocellular cancer, and nonsignificant for colon, breast, and prostate cancer.

New-Onset Diabetes With a History of Dyslipidemia Predicts Pancreatic Cancer

Dyslipidemia, but not diabetes, is a significant risk factor for PC and the link between diabetes and PC is likely due to confounders and detection bias.

Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients.

Chronic insulin therapy significantly increases the risk of colorectal cancer among type 1 diabetes mellitus patients and the positive association strengthened after adjusting for potential confounders.

Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden

No definitive conclusions regarding a possible causal relationship between insulin glargine use and the occurrence of malignancies can be drawn from the results of this study.

New Users of Metformin Are at Low Risk of Incident Cancer

Results suggest that metformin use may be associated with a reduced risk of cancer in people with type 2 diabetes, and a randomized trial is needed to assess whether met formin is protective in a population at high risk for cancer.

Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study

The results based on observational data support safety concerns surrounding the mitogenic properties of glargine in diabetic patients, and considering the overall relationship between insulin dose and cancer, the cancer incidence with glargin was higher than expected compared with human insulin.

Secular trend for mortality from breast cancer and the association between diabetes and breast cancer in Taiwan between 1995 and 2006

A secular trend of an increase in the rate of breast cancer mortality in the Taiwanese general population is identified and data suggest a higher risk of breastcancer mortality in diabetic patients in all age groups.

Is diabetes a causal agent for colorectal cancer? Pathophysiological and molecular mechanisms.

There is strong evidence to indicate that DM is a causal agent for CRC development, and this conclusion provides new impetus for re-evaluating CRC screening worldwide.